These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26058874)

  • 1. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.
    Xue TC; Jia QA; Ge NL; Chen Y; Zhang BH; Ye SL
    Tumour Biol; 2015 Nov; 36(11):8797-803. PubMed ID: 26058874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Xu X; Chen W; Zhang L; Miao R; Zhou Y; Wan Y; Dong Y; Liu C
    Chin Med J (Engl); 2014; 127(24):4204-9. PubMed ID: 25533822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
    Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
    PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization.
    Xue TC; Jia QA; Ge NL; Zhang BH; Wang YH; Ren ZG; Ye SL
    Tumour Biol; 2015 Aug; 36(8):6045-51. PubMed ID: 25731733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease following Chemoembolization of Hepatocellular Carcinoma.
    Cruz JC; Watchmaker JM; Albin MM; Wang L; Wu G; Baker JC; Fritsche MR; Alexopoulos SP; Matsuoka L; Fleming JW; Su J; Borgmann AJ; Banovac F; Brown DB
    J Vasc Interv Radiol; 2019 Dec; 30(12):1887-1892. PubMed ID: 31669086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
    Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
    Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization.
    Liu C; Jia BS; Zou BW; Du H; Yan LN; Yang JY; Jiang L; Wen TF; Lu WS
    Medicine (Baltimore); 2017 Nov; 96(45):e8512. PubMed ID: 29137051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
    BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation.
    Chen TM; Lin CC; Huang PT; Wen CF
    J Gastroenterol Hepatol; 2012 Mar; 27(3):553-61. PubMed ID: 21913982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases.
    McDermott SM; Saunders ND; Schneider EB; Strosberg D; Onesti J; Dillhoff M; Schmidt CR; Shirley LA
    J Surg Res; 2018 Dec; 232():369-375. PubMed ID: 30463743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma.
    Taussig MD; Irene Koran ME; Mouli SK; Ahmad A; Geevarghese S; Baker JC; Lipnik AJ; Banovac F; Brown DB
    HPB (Oxford); 2017 May; 19(5):458-464. PubMed ID: 28190710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.
    Xue T; Le F; Chen R; Xie X; Zhang L; Ge N; Chen Y; Wang Y; Zhang B; Ye S; Ren Z
    Med Oncol; 2015 Mar; 32(3):64. PubMed ID: 25682389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.